Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of ...
Ultomiris is a brand-name biologic medication prescribed for certain rare autoimmune disorders. Dosing of Ultomiris is done via intravenous (IV) infusions administered by a healthcare professional.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果